Cyprium Partners Adds Healthcare Expert Charles Sweet to Advisory Council
Cleveland, Ohio – Cyprium Partners announces the addition of healthcare expert, Charles Sweet to the Advisory Council. The Council is made up of experienced operating executives selected for their specialized industry backgrounds and complementary areas of functional expertise.
Charles Sweet has operated in numerous corporate executive and board-level roles over his thirty-year career. Representative healthcare experience includes physician practice management, hospital information systems, laboratory services, home healthcare, assisted living, hospice, prosthetics and orthotics, orthopedics, radiation oncology, and multi-specialty network management. Charles has been appointed to more than twenty private and public company boards with revenues ranging from $20 million to $500 million.
Mr. Sweet is President of IRC Consulting located in Boca Raton, Florida, an independent advisory practice he established in 1998. Among his previous achievements, Mr. Sweet also served as a managing director of an $8B private equity fund where he was responsible for the healthcare and information technology sectors, and he has served as CEO of seven companies.
“Cyprium is delighted to have Charles Sweet join us as an Advisory Council member. He brings a breadth of healthcare experience that will help us evaluate a wide range of business models, making us particularly relevant for healthcare operators and shareholders who are looking for an informed non-controlling investor.” said Mike Conaton, Managing Partner at Cyprium.
ABOUT CYPRIUM PARTNERS
Cyprium Partners is a private equity and mezzanine firm focused on profitable middle-market companies, allowing company owners and their management teams to retain a controlling interest in their businesses. Cyprium provides common equity, preferred stock, subordinated debt or any combination thereof, offering flexibility and increasing the certainty of close.
The Cyprium team is celebrating its 20th year and has deployed over $1.5 billion in 75 non-control investments. With offices in Cleveland, New York, and Chicago, the firm invests $10 million to $60 million per transaction in U.S. and Canadian companies with $8 million or more of EBITDA.